Organisation paid for research Program year 2025 Source: CMS Open Payments

CCT Research

Neither a doctor nor a teaching hospital

Research payments

$2,308,543

306 payments

Through program year 2025, CCT Research is reported as receiving $2,308,543 in research payments, across 306 payments.

By program year

5 rows
Year Kind Amount Payments
2025 Research $60 1
2024 Research $807,511 146
2023 Research $1,449,649 80
2022 Research $40,824 77
2021 Research $10,500 2

Breakdown

Who paid Research payments · program years 2021–2025
  1. Moderna TX, Inc. $1,815,731 106 payments
  2. Exact Sciences Corporation $335,168 8 payments
  3. Ipsen Innovation $91,078 109 payments
  4. Visby Medical, Inc. $27,435 8 payments
  5. Novartis Pharmaceuticals Corporation $16,875 2 payments
  6. ACADIA Pharmaceuticals Inc $12,177 3 payments
  7. Alnylam Pharmaceuticals Inc. $7,718 67 payments
  8. AstraZeneca UK Limited $2,306 2 payments
  9. Pfizer Inc. $56 1 payment
Studies the money was for Research payments · program years 2021–2025
  1. A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age $1,756,772 81 payments
  2. Informed Choice Intervention for Colorectal Cancer Screening - COMPASS $335,168 8 payments
  3. Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants $83,575 96 payments
  4. Observational secondary-use comparative effectiveness cohort study with tokenized clinical trial and real-world data. $49,425 5 payments
  5. A Prospective Collection of Vaginal Swab Samples from Subjects with Suspected Sexually Transmitted Infections for Verification and Validation Studies of the Visby Medical Sexual Health Test (Clinical Protocol No. TP-000033) $16,935 6 payments
  6. Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (Victorion-2 Prevent) $16,875 2 payments
  7. A Prospective Study to Collect Samples for Research and Development of Visby Medical Products Relating to Respiratory Infections (TP-000312) $10,500 2 payments
  8. Acp-103-046 $10,300 2 payments
  9. A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants $7,503 13 payments
  10. A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 $7,112 4 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record